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In his editorial in the February 2011 issue of Cellular
Oncology Gerrit Meijer pointed out that with the onset
of the second decade of this century ‘many of us expect to
witness the full maturation of omics being turned into
diagnostic and therapeutic applications that will improve
clinical outcome in many diseases, including oncology’. It
has indeed been advocated for some time that one day we
may stratify patients using in-depth omics analyses.
Thanks to the diminishing costs and increasing speed of
high-throughput technologies this era has now begun, and
tabletop instruments with the ability to genotype and
analyze patient samples in less than 45 min are well
underway. In the recent past, several laboratories around
the world have teamed up in the International Cancer
Genome Consortium (ICGC) following the launch of
comprehensive cancer genome projects in the UK and
the USA, and the sequences of cancer genomes are being
published now at an increasingly rapid pace. Based on
these developments, a growing list of companies and
hospitals have begun to employ next generation sequen-
cing technologies to identify relevant mutations across
genomes for diagnostic and prognostic purposes, and to
apply them to potentially targeted therapies. In spite of
these exciting developments, however, several questions
remain, including uncertainties about whether our under-
standing of the cancer genome is already advanced
enough to make a comprehensive use of these technolo-
gies effective. Indeed, the biological relevance of many
sequence variants is, as yet, poorly understood. To meet
this interpretational challenge, it will be essential to com-
bine the expertise of geneticists, pathologists, oncologists and
bio-informaticians, and to validate preclinical results in well-
characterized population-based cohorts and randomized clin-
ical trials. The ultimate clinical adoption of omics technolo-
gies will require broad collaborations across researchers,
industries, health care workers and policy makers.
Over the last several years Cellular Oncology has
played an increasingly prominent role in covering topics
related to the pathogenesis of cancer, the development of
new technologies and its application to early diagnosis
and optimized patient stratification for personalized treat-
ment. Gerrit Meijer has significantly contributed to the
strong position of the journal in these fields of oncology
and we owe him and his editorial team much gratitude for
that. During the combined ISCO-EWCMST meeting at La
Palma de Mallorca, Spain earlier this year (see report in
this issue) he has handed over this task to a new team
that, together with Springer and ISCO, has taken on the
challenge to move the field of cellular oncology to a next
level and to contribute to the prospect that lies ahead of
us, i.e., the maturation of omics technologies into com-
prehensive diagnostic and therapeutic applications. In or-
der to engage in this challenge, the new editorial team
strongly encourages scientists from various disciplines to
contribute to the journal, not only their original research
work, but also state-of-the-art reviews to update peers and
all those interested on the rapidly changing landscapes in
cellular oncology.
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